Published in Eur J Clin Pharmacol on January 01, 1986
Cefodizime in serum and skin blister fluid after single intravenous and intramuscular doses in healthy volunteers. Antimicrob Agents Chemother (1987) 0.99
Pharmacokinetic study of cefodizime and ceftriaxone in sera and bones of patients undergoing hip arthroplasty. Antimicrob Agents Chemother (1997) 0.76
Multiple-dose pharmacokinetics of ofloxacin in serum, saliva, and skin blister fluid of healthy volunteers. Antimicrob Agents Chemother (1990) 0.75
Pharmacokinetic profile of cefodizime. Infection (1992) 0.75
P2X1 and P2X3 receptors form stable trimers: a novel structural motif of ligand-gated ion channels. EMBO J (1998) 3.23
Antagonist binding profiles of five cloned human muscarinic receptor subtypes. J Pharmacol Exp Ther (1991) 2.55
Comparison of the antibacterial in vitro and in vivo activity of ofloxacin (HOE 280 DL 8280) and nalidixic acid analogues. Eur J Clin Microbiol (1983) 2.45
PPADS, a novel functionally selective antagonist of P2 purinoceptor-mediated responses. Eur J Pharmacol (1992) 2.43
Successful treatment of severe refractory atopic dermatitis with mycophenolate mofetil. Br J Dermatol (1999) 1.96
Differential expression of secreted aspartyl proteinases in a model of human oral candidosis and in patient samples from the oral cavity. Mol Microbiol (1998) 1.70
PPADS selectively antagonizes P2X-purinoceptor-mediated responses in the rabbit urinary bladder. Br J Pharmacol (1993) 1.69
Secreted aspartic proteinase (Sap) activity contributes to tissue damage in a model of human oral candidosis. Mol Microbiol (1999) 1.69
Vitamin A loaded solid lipid nanoparticles for topical use: occlusive properties and drug targeting to the upper skin. Eur J Pharm Biopharm (2000) 1.58
The pH of the skin surface and its impact on the barrier function. Skin Pharmacol Physiol (2006) 1.55
[The antibacterial activity in vitro of ofloxacin in comparison with other orally administered antimicrobial substances on ampicillin-resistant clinical isolates]. Arzneimittelforschung (1984) 1.50
Mersacidin, a new antibiotic from Bacillus. In vitro and in vivo antibacterial activity. J Antibiot (Tokyo) (1992) 1.44
Invasion of human keratinocytes by Staphylococcus aureus and intracellular bacterial persistence represent haemolysin-independent virulence mechanisms that are followed by features of necrotic and apoptotic keratinocyte cell death. Br J Dermatol (2002) 1.42
[Structure-activity relationship of N-methyl-3-pyrroline and N-methyl-pyrrolidine-3-carboxylic acid]. Arzneimittelforschung (1971) 1.40
[Pyoderma]. Hautarzt (1998) 1.37
Study of the contractile effect of 5-hydroxytryptamine (5-HT) in the isolated longitudinal muscle strip from guinea-pig ileum. Evidence for two distinct release mechanisms. Naunyn Schmiedebergs Arch Pharmacol (1985) 1.36
[Structure-activity relationships of unsaturated esters of arecaidine and dihydroarecaidine]. Arzneimittelforschung (1973) 1.35
Involvement of cyclic AMP in the direct inotropic action of amrinone. Biochemical and functional evidence. Naunyn Schmiedebergs Arch Pharmacol (1981) 1.32
Pharmacokinetic properties of the new cephalosporin antibiotic HR 810 in animals. Infection (1984) 1.28
Vasoconstrictor and vasodilator responses to various agonists in the rat perfused mesenteric arterial bed: selective inhibition by PPADS of contractions mediated via P2x-purinoceptors. Br J Pharmacol (1994) 1.27
Selective antagonism by PPADS at P2X-purinoceptors in rabbit isolated blood vessels. Br J Pharmacol (1994) 1.27
HR 810, a new parenteral cephalosporin with a broad antibacterial spectrum. Arzneimittelforschung (1983) 1.27
Renal function in the elderly: impact of hypertension and cardiac function. Kidney Int (1997) 1.27
Interaction of metoprolol, propranolol and atenolol with concurrent administration of cimetidine. Klin Wochenschr (1982) 1.26
Cefodizime, an aminothiazolyl cephalosporin. IV. Influence on the immune system. J Antibiot (Tokyo) (1984) 1.25
Influence of serum protein binding on the in vitro activity of anti-fungal agents. Infection (1996) 1.23
Interaction of cimetidine with metoprolol, propranolol, or atenolol. Lancet (1981) 1.22
Vitamin A-loaded solid lipid nanoparticles for topical use: drug release properties. J Control Release (2000) 1.21
Hyaluronic acid in the treatment and prevention of skin diseases: molecular biological, pharmaceutical and clinical aspects. Skin Pharmacol Physiol (2004) 1.19
Late cutaneous schistosomiasis representing an isolated skin manifestation of schistosoma mansoni infection. Dermatology (2000) 1.19
Investigation of the actions of PPADS, a novel P2x-purinoceptor antagonist, in the guinea-pig isolated vas deferens. Br J Pharmacol (1994) 1.18
Fluorimetric determination of atenolol in plasma and urine by direct evaluation of thin-layer chromatograms. J Chromatogr (1979) 1.18
Fluorimetric determination of oxprenolol in plasma by direct evaluation of thin-layer chromatograms. J Chromatogr (1979) 1.17
[Normal pH value of human skin]. Hautarzt (1986) 1.16
p-fluoro-hexahydro-sila-difenidol: the first M2 beta-selective muscarinic antagonist. Eur J Pharmacol (1988) 1.16
Coadministration of albumin and furosemide in patients with the nephrotic syndrome. Kidney Int (1999) 1.14
Mechanisms of adherence of Candida albicans to cultured human epidermal keratinocytes. Infect Immun (1993) 1.14
Antimuscarinic action of methoctramine, a new cardioselective M-2 muscarinic receptor antagonist, alone and in combination with atropine and gallamine. Eur J Pharmacol (1987) 1.13
Influence of albumin on itraconazole and ketoconazole antifungal activity: results of a dynamic in vitro study. Antimicrob Agents Chemother (1991) 1.13
Pharmacological characterization of the vascular muscarinic receptors mediating relaxation and contraction in rabbit aorta. J Pharmacol Exp Ther (1991) 1.12
An improved high-performance liquid chromatographic method for the determination of sphingosine-1-phosphate in complex biological materials. Naunyn Schmiedebergs Arch Pharmacol (2001) 1.11
Functional role in ligand binding and receptor activation of an asparagine residue present in the sixth transmembrane domain of all muscarinic acetylcholine receptors. J Biol Chem (1994) 1.07
Increased expression of Candida albicans secretory proteinase, a putative virulence factor, in isolates from human immunodeficiency virus-positive patients. J Clin Microbiol (1995) 1.07
Invasion of Candida albicans correlates with expression of secreted aspartic proteinases during experimental infection of human epidermis. J Invest Dermatol (2000) 1.07
The in-vitro antibacterial activity of a combination of cefpirome or cefoperazone with vancomycin against enterococci and Staphylococcus aureus. J Antimicrob Chemother (1992) 1.07
Characterisation of penicillinase producing gonococci isolated in Munich, 1981-6. Genitourin Med (1988) 1.02
Pharmacokinetics of cefpirome (HR 810), a new cephalosporin derivative administered intramuscularly and intravenously to healthy volunteers. Infection (1987) 1.01
Affinity profiles of hexahydro-sila-difenidol analogues at muscarinic receptor subtypes. Eur J Pharmacol (1989) 1.01
Antibacterial activities in vitro and in vivo and pharmacokinetics of cefquinome (HR 111V), a new broad-spectrum cephalosporin. Antimicrob Agents Chemother (1991) 1.00
Cefodizime, an aminothiazolylcephalosporin. II. Comparative studies on the pharmacokinetic behavior in laboratory animals. J Antibiot (Tokyo) (1984) 1.00
Muscarinic receptors mediating acid secretion in isolated rat gastric parietal cells are of M3 type. Gastroenterology (1990) 1.00
Dose linearity testing of intravenous cefpirome (HR 810), a novel cephalosporin derivate. Infection (1987) 1.00
1Alpha,25-dihydroxyvitamin D3 protects human keratinocytes from apoptosis by the formation of sphingosine-1-phosphate. J Invest Dermatol (2001) 0.99
[Morphologic variants of genital ulcer caused by Haemophilus ducreyi]. Hautarzt (1989) 0.99
Cefodizime in serum and skin blister fluid after single intravenous and intramuscular doses in healthy volunteers. Antimicrob Agents Chemother (1987) 0.99
Treatment of tinea unguium with medium and high doses of ultramicrosize griseofulvin compared with that with itraconazole. Antimicrob Agents Chemother (1993) 0.98
Levels of itraconazole in skin blister fluid after a single oral dose and during repetitive administration. J Am Acad Dermatol (1990) 0.98
The role of vitamin E in normal and damaged skin. J Mol Med (Berl) (1995) 0.97
Inhibitory action of PPADS on relaxant responses to adenine nucleotides or electrical field stimulation in guinea-pig taenia coli and rat duodenum. Br J Pharmacol (1995) 0.96
The role of Candida albicans secreted aspartic proteinase in the development of candidoses. J Mol Med (Berl) (1996) 0.96
Presynaptic muscarinic receptors mediating inhibition of neurogenic contractions in rabbit vas deferens are of the ganglionic M1-type. Eur J Pharmacol (1988) 0.96
Single and multiple dose pharmacokinetics of intravenous cefpirome (HR 810), a novel cephalosporin derivative. Infection (1987) 0.96
Antimicrobial susceptibility testing of dermatophytes--comparison of the agar macrodilution and broth microdilution tests. Chemotherapy (1998) 0.96
Is tinea unguium still widely incurable? A review three decades after the introduction of griseofulvin. Arch Dermatol (1992) 0.95
Anti-microbial and -inflammatory activity and efficacy of phytosphingosine: an in vitro and in vivo study addressing acne vulgaris. Int J Cosmet Sci (2007) 0.95
o-Methoxy-sila-hexocyclium: a new quaternary M1-selective muscarinic antagonist. Eur J Pharmacol (1988) 0.95
Reconstructed epidermis versus human and animal skin in skin absorption studies. Toxicol In Vitro (2005) 0.95
[On the microbiological conversion of N-containing substrates. 4. On the microbiological conversion of 5-hydroxyindole through Clavic eps purpurea, Cordyceps militaris and Aspergillus oryzae]. Arch Pharm Ber Dtsch Pharm Ges (1968) 0.95
Current and future approaches to antimycotic treatment in the era of resistant fungi and immunocompromised hosts. Int J Antimicrob Agents (2001) 0.95
Influence of ranitidine on plasma metoprolol and atenolol concentrations. Br Med J (Clin Res Ed) (1983) 0.95
Chemotherapeutic effects of ofloxacin (HOE 280) and other quinolone-carboxylic derivates in the treatment of experimental lung infections due to Klebsiella pneumoniae DT-S in mice. Infection (1986) 0.95
The influence of cardiovascular and antiinflammatory drugs on thiazide-induced hemodynamic and saluretic effects. Eur J Clin Pharmacol (2006) 0.95
Atenolol interaction with aspirin, allopurinol, and ampicillin. Clin Pharmacol Ther (1983) 0.94
Time course and extent of angiotensin II antagonism after irbesartan, losartan, and valsartan in humans assessed by angiotensin II dose response and radioligand receptor assay. Clin Pharmacol Ther (1999) 0.94
The KEX2 gene of Candida glabrata is required for cell surface integrity. Mol Microbiol (2001) 0.94
Onychomycosis. Mycoses (2007) 0.94
Different binding affinities of NMDA receptor channel blockers in various brain regions--indication of NMDA receptor heterogeneity. Neuropharmacology (1995) 0.94
NF279: a novel potent and selective antagonist of P2X receptor-mediated responses. Eur J Pharmacol (1998) 0.94
Diuretic effectiveness of hydrochlorothiazide and furosemide alone and in combination in chronic renal failure. J Cardiovasc Pharmacol (1995) 0.94
Sequential nephron blockade breaks resistance to diuretics in edematous states. J Cardiovasc Pharmacol (1997) 0.93
Aquarium dermatitis: cercarial dermatitis in an aquarist. Dermatology (1998) 0.93
Vasoconstrictor responses via P2X-receptors are selectively antagonized by NF023 in rabbit isolated aorta and saphenous artery. Br J Pharmacol (1997) 0.93
Characterization of the prejunctional muscarinic receptors mediating inhibition of evoked release of endogenous noradrenaline in rabbit isolated vas deferens. Naunyn Schmiedebergs Arch Pharmacol (1994) 0.93
Actinic keratosis: the key event in the evolution from photoaged skin to squamous cell carcinoma. Therapy based on pathogenetic and clinical aspects. Skin Pharmacol Physiol (2004) 0.92
Increase in magnesium plasma level after orally administered trimagnesium dicitrate. Eur J Clin Pharmacol (1996) 0.92
Characterization of muscarinic receptors mediating vasodilation in rat perfused kidney. Eur J Pharmacol (1993) 0.92
Methoctramine selectively blocks cardiac muscarinic M2 receptors in vivo. Naunyn Schmiedebergs Arch Pharmacol (1988) 0.92
Human HT-29 colon carcinoma cells contain muscarinic M3 receptors coupled to phosphoinositide metabolism. Eur J Pharmacol (1989) 0.92
Effects of pentoxifylline on red blood cell deformability and blood viscosity under hyperosmolar conditions. Naunyn Schmiedebergs Arch Pharmacol (1977) 0.92
Plasmid content and protein I serovar of non-penicillinase-producing gonococci isolated in Munich. Epidemiol Infect (1988) 0.92
Limitation on the use of amiloride in early renal failure. Eur J Clin Pharmacol (1985) 0.92